Domestic bio companies engaged in new drug development are shifting to a full-fledged profit-generating structure through technology exports and sales of their own new drugs. Unlike in the past, when it was common to remain in the red for a long period after listing, there have recently been a series of cases in which companies post profits from the first year of listing or renew record-high earnings. The assessment is that the bio industry, long perceived as research and development-centered, is moving into a phase where it generates tangible profits.


Upfront payments and milestone revenues from technology transfer, together with sales of proprietary new drugs, are being reflected at the same time, improving the quality of earnings. Analysts say a virtuous cycle is beginning to take hold in which research achievements are translated into cash flow, and these funds are then reinvested into follow-up pipelines. However, some point out that going forward it will be necessary to evolve beyond simple technology transfer into collaborative models that share development risks and know-how with global pharmaceutical companies.

Korean New Drug Developers Move Beyond Technology Milestones Into the Profitability Phase View original image

Meanwhile, interest in stock loans is increasing day by day. This is because investors who do not want to miss rare investment opportunities are turning their attention to stock loans, which allow them to use more funds for stock purchases.


Another advantage of stock loans is that even if investors using margin or credit trading face a forced liquidation crisis due to a sharp stock price drop, they can simply switch over without providing additional collateral or selling holdings, and then wait for a rebound.


◆ All New Stock Loan, from products with the lowest annual interest rate in the 5% range to products exempt from DSR application!

All New Stock Loan has launched a securities-linked credit product with the industry's lowest interest rate in the annual 5% range so that any investor can use stock loans without burden. It can be used not only for stock purchases but also for refinancing both margin and credit loans from securities firms, and up to four times the investor's own capital can be utilized regardless of credit rating.


In addition, it offers products that are not affected by the DSR limit for investors who previously had difficulty using stock loans due to DSR constraints. Investors using the alternative trading system (NXT) can also take advantage of these services.


Investors who want to know more about All New Stock Loan can contact the customer service center (☎1599-8666) and conveniently consult with a professional advisor at any time, regardless of whether they ultimately take out a loan.


○ Launched products with the industry's lowest annual interest rate in the 5% range!

○ Regardless of existing loan balance or income! (Not subject to DSR)

○ Ability to use up to four times your own capital as stock investment funds! (Including your own funds)

○ Same-day, immediate refinancing of securities credit/margin loans available!

○ Trading on the alternative trading system (NXT) is available

○ Stocks that were difficult to purchase with existing securities firm credit or stock loan services are also OK!

* All New Stock Loan Customer Service Center: 1599-8666

Direct link: https://allnewstockloan.co.kr?agency=HTS


Hanwha Ocean, Mirae Asset Securities, Yuhan, POSCO Holdings, ABL Bio



※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing